Which best describes your experience with TGCT
(also known as PVNS or GCT-TS)?
See how others responded: X50% I am currently managing a patient with TGCT. 30% I am not currently managing a patient with TGCT, but I have in the past. 20% I have never managed a patient with TGCT.
While many TGCT cases can be resolved with one surgery, patients with recurrent, diffuse, or
difficult-to-treat TGCT may benefit from team-based care. A specialized oncology or sarcoma
center can help support potential long-term management needs for patients with TGCT.
Click here to learn more about TGCT treatment.
TGCT can be difficult to diagnose. Patients may see many physicians, undergo
various tests, and receive multiple misdiagnoses before being diagnosed with TGCT.
Click here to learn more about the signs and symptoms of TGCT.
Tenosynovial giant cell tumor (TGCT), also known as pigmented villonodular synovitis (PVNS) or giant cell tumor of the tendon sheath (GCT-TS), is a group of rare tumors that typically arises from the
synovium of joints, bursae, and tendon sheaths.1-3 They are typically non-malignant neoplasms but
can be locally aggressive.1,4
TGCT encompasses 2 broad subtypes—diffuse and localized—that differ clinically but share a common etiology.1
A multidisciplinary team of experts can help create a plan to address the long-term management needs of patients with difficult-to-treat TGCT.3,5
Differences in TGCT by subtype
a Subtypes as classified by the World Health Organization.
TGCT can be difficult to diagnose because it presents with symptoms of many other conditions.16 Once diagnosed, it may take a multidisciplinary team of experts to create a plan to address patients’ long-term management needs.3,5
Whether tumors are localized or diffuse can
affect the prognosis of patients.1,8,17